Halberd Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William A. Hartman
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- PO Box 25 Jackson Center PA United States of America 16133
- IPO Date
- Sep 25, 2012
- CIK
- 0001458631
- Website
- halberdcorporation.com
- Similar Companies
- Business
- Halberd Corporation (OTC: HALB) develops therapeutic solutions targeting neurodegenerative diseases, blood-borne pathogens, infectious conditions and cancer through its patented extracorporeal treatment technologies, low-dose naltrexone formulations and AI-enhanced behavioral analysis platforms; core offerings encompass extracorporeal pathogen removal systems for cerebral spinal fluid and blood applications, LDN+ patented compounds for pain, anxiety, PTSD, addiction and dialysis-related neuropathy/pruritis, patent-pending TBI nasal sprays to mitigate post-head-trauma neurodegeneration, NeuroSense AI behavioral intelligence platform integrating ultrasonic vocalization, micro-movement tracking and social monitoring for preclinical and clinical TBI assessment, plus antibody-drug conjugates and laser/radio frequency therapies for Alzheimer's, Parkinson's, epilepsy, chemical dependencies and sepsis. The biotechnology company, founded in 2009 and headquartered in Jackson Center, Pennsylvania, operates primarily in the United States with research collaborations including Mississippi State University and strategic alliances across North America; subsidiaries include NeuroSense AI Corp., Alaric Corporation and Extendalife Inc. Recent developments feature the September 2025 acquisition of NeuroSense AI Corp. to bolster TBI research with multi-modal AI analytics, a November 2025 pursuit of U.S. government contracts for Phase-2 animal studies on TBI nasal spray funded via Mississippi State collaboration, ongoing 2025 clinical efficacy demonstrations of LDX compound through nationwide nephrologist solicitations with Athena Telemedicine Partners for 100-patient kidney disease trials, and continued joint ventures with Athena GTX for non-dilutive funding alongside prior 2023-2024 distribution agreements with CrodenHealth Corp. for LDN+ commercialization.
Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
Halberd Update on WatchDawg® PTSD Treatment
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Halberd Corp. Issues Letter to Shareholders
Halberd Corp. Issues Letter to Shareholders
Halberd Corp's (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans